ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1373 National Cancer Institute Html en Cervical Cancer Screening (PDQ®)–Health Professional Version Expert-reviewed information summary about tests used to detect or screen for cervical cancer.
Obstet Gynecol0.581628
Hysterectomy-corrected cervical cancer0.555295
HPV DNA testing0.788756
cervical cancer worldwide0.552556
American Cancer Society0.524538
cervical sample collection0.524565
Int J Cancer0.522908
cervical screening0.611205
cervical neoplasia0.571227
cervical screening studies0.563298
human papillomavirus dna0.532798
mild cervical dysplasia0.520991
HPV testing0.581414
cervical cancer mortality0.721474
cervical cancer screening0.742524
CIN0.553434
Natl Cancer Inst0.615845
cervical cancer0.995918
cervical squamous cell0.556962
cervical human papillomavirus0.547211
HPV DNA arm0.52076
cervical cytology cotesting0.564531
human papillomavirus0.694632
cervical cancer death0.561576
high-grade cervical lesions0.559164
cervical cancer incidence0.597514
atypical squamous cells0.549121
et al.0.515402
women0.616944
cervical cytology0.628179
cervical cancer detection0.553165
PUBMED Abstract0.530353
invasive cervical cancer0.658472
repeat HPV DNA0.513096
cervical screening programmes0.542296
conventional cervical smear0.513052
primary cervical cancer0.570395
abnormal cervical cancer0.542326
cervical cancer risks0.549122
Abstract0.599358
Cervical cancer control0.552963
cervical cytologic abnormalities0.517315
invasive cervical cancers0.51155
cervical intraepithelial neoplasia0.648604
hpv dna test0.564095
squamous intraepithelial lesions0.555418
cervical cytologic0.523009
cervical cancer cases0.567527
Cervical cancer risk0.551241
CLICK HERE
1389 National Cancer Institute Html en Breast Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of ductal carcinoma in situ, lobular carcinoma in situ, and invasive breast cancer.
adjuvant chemotherapy0.413465
primary breast cancer0.408571
Breast cancer prognosis0.425608
MammaPrint breast cancer0.413079
breast cancer patient0.414699
Engl J Med0.524403
Breast Cancer Family0.427508
Breast Cancer Linkage0.421472
Breast Cancer Cooperative0.407872
15-year breast cancer0.406317
her2-positive breast cancer0.442543
early-stage breast cancer0.442314
Radiat Oncol Biol0.416027
triple-negative breast cancer0.428166
node-positive breast cancer0.499527
breast cancer patients0.48801
operable breast cancer0.439264
Natl Cancer Inst0.634346
benign breast disease0.41282
receptor-negative breast cancer0.410906
surgical adjuvant breast0.46168
-negative breast cancer0.425377
breast cancer death0.425817
invasive breast cancer0.473025
et al.0.549932
contralateral breast cancer0.442652
early breast cancer0.60357
early-onset breast cancer0.418149
stage breast cancer0.414667
lobular breast cancer0.425161
age-specific breast cancer0.41613
PUBMED Abstract0.428161
node-negative breast cancer0.45155
T1 breast cancer0.412562
breast cancer risk0.490957
International Breast Cancer0.418134
Abstract0.568891
Clin Oncol0.680872
Danish Breast Cancer0.425148
breast cancer0.97463
Oncol Biol Phys0.418084
Breast Cancer Trialists0.422554
breast cancer mortality0.404968
Breast Cancer Study0.420746
oestrogen-receptor-positive breast cancer0.416419
breast cancer incidence0.439577
subsequent breast cancer0.429086
advanced breast cancer0.411746
Breast Cancer Res0.494855
CLICK HERE
1709 National Cancer Institute Html en Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ®)–Health Professional Version Hereditary kidney cancer (renal cell cancer) syndromes include von Hippel-Lindau disease, hereditary leiomyomatosis and renal cell cancer, Birt-Hogg-Dubé syndrome, and hereditary papillary renal carcinoma. Learn about the genetics, clinical manifestations, and management of these hereditary cancer syndromes in this expert-reviewed summary.
Renal cell cancer0.417461
sporadic renal cell0.38738
renal pelvis cancer0.39949
hereditary renal tumors0.379064
renal tumors0.424533
solid-enhancing renal masses0.375815
marginal renal function.0.376092
Hippel-Lindau tumor suppressor0.449329
cell renal cell0.422508
renal replacement therapy0.383629
renal parenchymal sparing0.388349
von Hippel-Lindau families0.43492
Hippel-Lindau tumour suppressor0.410095
von hippel-lindau disease0.900395
von hippel-lindau0.920724
von Hippel Lindau0.387864
advanced von Hippel-Lindau0.430231
salvage renal surgery0.382297
Hippel-Lindau protein mutants0.39948
von Hippel-Lindau ubiquitylation0.442871
small renal mass0.378802
von Hippel-Lindau gene0.462044
et al.0.556118
small renal masses0.392859
sporadic renal masses0.379735
renal functional outcomes0.377613
papillary renal cell0.383702
renal carcinomas0.373668
renal tubules0.373542
hereditary renal cancer0.400308
renal disease0.379225
ocular von Hippel-Lindau0.464552
renal medulla0.3796
VHL0.386773
von Hippel-Lindau tumor0.479006
tumor suppressor gene0.380161
Bilateral renal cell0.380325
Abstract0.55535
Hippel-Lindau disease tumor0.448931
von Hippel-Lindau patients0.465787
sporadic renal carcinoma.0.386645
renal cell carcinoma0.660911
Hippel-Lindau gene mutations0.398567
Hippel-Lindau protein promotes0.402255
von Hippel-Lindau protein0.50858
von hippel-lindau syndrome0.558083
clear-cell renal cell0.409767
Hum Genet0.372826
von Hippel-Lindau mutation0.438746
CLICK HERE
1808 National Cancer Institute Html es Tratamiento del cáncer de pulmón de células no pequeñas (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células no pequeñas.
Lung Cancer Cooperative0.316467
mortality from lung0.310666
lung carcinoma0.31822
prognostic factors0.309508
Lung Cancer Study0.332966
smokers with lung0.309535
lung cancer0.992251
Fontanini G0.305117
resected lung carcinoma0.312389
diferenciación neuroendocrina0.305367
Lung Cancer Group0.316997
Low-dose lung computed0.309521
Sloan Kettering Cancer0.307926
Natl Cancer Inst0.341191
M1b designa metástasis0.305741
non-small cell lung0.414109
non-small cell carcinoma0.312588
Beta-Carotene Cancer Prevention0.308204
childhood cancer0.312632
exploraciones tep-fdg0.306389
second primary tumors0.304786
Lancet Oncol0.30753
IA IIA IIIA0.306611
completely resected0.309471
Determinados pacientes0.308475
or lung0.308858
Lung Cancer Staging0.315082
with lung adenocarcinomas0.317245
Beta Carotene Cancer0.308891
Lung Cancer Mutation0.316077
múltiples ganglios0.306855
Thorac Cardiovasc Surg0.327776
Cancer Prevention Study0.316196
resected stage0.304849
Staging Lung Cancer0.325211
tirosina cinasa0.308791
Clin Oncol0.307174
cell lung carcinoma0.313583
estadio iii0.305092
Cancer Head0.307751
Thorac Surg0.348681
Cancer Survivor Study0.309329
M0 non-small-cell lung0.309712
non-small-cell lung0.365087
air pollution0.305452
IIA IIIA0.307286
resected non-small-cell lung0.310765
Cancer Study Group0.318777
Cardiothorac Surg0.307325
CLICK HERE
1837 National Cancer Institute Html es Tratamiento del cáncer de pene (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene.
Horenblas S0.510336
Nielsen OS0.509173
Compton CC0.557867
therapy with cisplatin0.51114
alta incidencia0.509039
Russo P0.509584
Ta Carcinoma0.513251
radical inguinal lymphadenectomy0.511322
invasive carcinoma0.512611
Urologic Cancer0.517007
7th ed0.565184
linfadenectomía profiláctica0.526988
Radiat Oncol Biol0.519915
Verrucous carcinoma0.511779
papillomavirus-associated penile squamous0.511778
epidermoid carcinoma0.511036
retrospective analysis0.533675
papillomavirus dna0.511396
8th ed0.50889
típico carcinoma0.513162
Waters WB0.509049
Lindegaard JC0.509948
human papillomavirus0.555341
Catalona WJ0.510454
Javadpour N0.50987
estadio iv0.51387
Neoadjuvant therapy with0.511141
Surg Pathol0.512914
Microscopically controlled surgery0.510476
Perez CA0.516876
Reda DJ0.508824
Harty JI0.510648
Surgical treatment0.514704
Cancer Staging Manual0.614394
carcinoma with0.51364
treatment with0.51195
carcinoma basaloide0.513292
New York0.574898
Lundbeck FA0.510525
sentinel node biopsy0.508574
Oncol Biol Phys0.520345
squamous cell carcinomas0.95738
Ornellas AA0.50861
Byrd DR0.554153
Zhang ZF0.510317
treated with0.512687
Acta Oncol0.509033
Tis Carcinoma0.513411
AJCC Cancer Staging0.617972
CLICK HERE
1891 National Cancer Institute Html es Tratamiento del cáncer de ano (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer de ano.
estadio iiia0.66246
PDQ Tratamiento0.368709
habitual.ampliar examen0.387381
siguientes procedimientos0.837689
presente sección0.355
estadio iv0.612941
partes distantes0.37408
Physician Data Query0.438142
pequeña cantidad0.386366
siguientes sitios0.532884
vía oral0.366291
rayos x0.386262
largo.ampliar anatomía0.405333
músculos esfínteres0.960462
ondas sonoras0.395446
sexo anal0.419097
ensayos clínicos.Radiosensibilizadores0.472666
National Cancer Institute0.330413
siguientes riesgos0.324935
realidad células0.417931
siguientes pruebas0.419418
aberturas anormales0.403318
Instituto Nacional0.364795
CLICK HERE
2044 National Cancer Institute Html es Prevención del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para pacientes Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de ovario, de trompas de Falopio y primario de peritoneo y sobre las investigaciones dirigidas a prevenir los mismos.
antecedentes familiares0.933166
siguientes factores0.609631
voluntarios sanos0.462464
Physician Data Query0.683225
Gynecologic Cancers0.476797
PDQ Genetics0.581563
suficiente ejercicio0.49551
ligero aumento0.489896
prevención revisa0.462583
Risk-reducing salpingo-oophorectomy0.476848
PDQ Prevención0.518021
pequeño riesgo0.673978
Sudores nocturnos0.477347
Características genéticas0.468946
National Cancer Institute0.471922
siguientes riesgos0.45943
genes brca10.79957
siguientes sumarios0.611077
largo tiempo0.470563
Instituto Nacional0.533142
CLICK HERE
3462 National Cancer Institute Html es Temas sobre terapias integrales, alternativas y complementarias (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos de información sobre las terapias integrales, alternativas y complementarias para personas con cáncer.
PDQ Complicaciones0.330259
PDQ Cannabis0.362872
Flor Essence0.356993
PDQ PC-SPES0.334586
Selected Vegetables0.376666
PDQ Extractos0.333699
PDQ Antineoplastones0.329438
accessed october0.324198
PDQ Essiac0.335262
Sloan-Kettering Cancer Center0.320538
St John wort0.340246
Instituto Nacional0.314846
PDQ Adaptación0.351677
PDQ Cardo mariano0.33478
PDQ 714-X0.329593
San Juan mejora0.31086
PDQ Terapia Gerson0.332429
PDQ Fatiga0.386733
coenzima q100.35227
Estados Unidos0.382317
Natl Cancer Inst0.325675
PDQ Aromaterapia0.331428
PDQ Coenzima Q100.33404
pdq trastornos0.419665
PDQ Náuseas0.362198
john's wort0.491912
Hypericum perforatum0.31143
PDQ Virus0.328157
Memorial Sloan-Kettering Cancer0.320906
Sun's Soup0.37427
PDQ Linfedema0.333129
hierba sonajero0.351314
PDQ Régimen Gonzalez0.331941
PDQ Dosis0.32955
alternative medicine0.32239
PDQ Acupuntura0.335041
PDQ Depresión0.334266
PDQ Temas0.326936
PDQ Sulfato0.329102
PDQ Selected Vegetables0.333719
PDQ Cartílago0.329719
enzimas pancreáticas0.310494
radicales libres0.344931
cartílago bovino0.31037
PDQ Laetrilo0.329062
san juan0.946893
John's wort constituent0.30988
PDQ Sofocos0.397756
PDQ Cáncer0.592196
CLICK HERE
3855 National Cancer Institute Html es Tratamiento del cáncer sin daño al corazón Investigadores de los campos de oncología y de cardiología están trabajando para encontrar formas de impedir, manejar y posiblemente aun revertir los efectos secundarios cardiovasculares de ciertas terapias del cáncer.
doctora minasian0.420648
Toxicidad Cardiovascular0.397361
funciones cardíacas0.389495
oncología comunitaria suncoast0.499346
Estudio PREDICT0.431531
doctores edward t.h0.46464
Eileen Dimond0.383363
Más gente0.39382
Cancer Center0.835847
Instituto Nacional0.378255
evento coronario0.384904
necesaria investigación0.396051
Gregory Hundley0.381508
uso del lisinopril0.382252
NCI.“El NCI0.483538
mayores aumentos0.393722
bloqueador beta0.384896
cuestión provocativa número0.450757
alto riesgo0.61435
doctor saro armenian0.462785
Mayo Clinic0.37936
enfermedad isquémica cardíaca0.538111
carvedilol fosfato0.395021
Anderson Cancer Center0.780116
editorial anexo0.379604
Dana-Farber Cancer Institute0.454758
Brigada Comunitaria0.385219
efectos tardíos0.687242
Pimprapa Vejpongsa0.386075
Wake Forest Baptist0.436151
doctor gregory t0.449856
futuras investigaciones0.386679
efectos secundarios cardíacos.Sustancias0.621707
MD Anderson Cancer0.78917
médicos oncólogos0.393733
supervivientes adultos0.958505
cardiopatía coronaria0.411854
Jude Children´s Research0.445325
corto plazo0.380257
Vanderbilt-Ingram Cancer Center0.454856
doctora sarah c0.467574
doctora pooja p0.468177
Estudio USF0.426971
doctor javid moslehi0.464739
doctor w0.384312
largo tiempo0.383822
doctora lori minasian0.500028
doctor moslehi0.395708
CLICK HERE
15878 National Cancer Institute Html es Antineoplastones (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos sobre los antineoplastones como tratamiento para personas con cáncer.
with antineoplaston a20.218822
Investigación Burzynski0.22067
with antineoplastons0.246694
Exp Clin Res0.800411
antineoplastón a100.397658
Initial clinical study0.211468
prostate with antineoplaston0.217616
Purified Antineoplaston Fractions0.215376
antineoplaston a100.272621
pacientes nimustina0.213052
antineoplastons a100.222443
Clin Proc0.222323
study with antineoplaston0.218319
Veinte pacientes0.213707
antineoplastón a30.224113
chemoradiation therapy with0.212987
Oncol Rep0.240747
Soc Exp Biol0.215807
patients with0.222048
Physiol Chem Phys0.238091
antineoplastones a100.278317
pacientes respuesta0.221956
Burzynski SR0.970231
Kubove E0.284007
US Patent0.217212
antineoplaston a10 with0.212999
Antineoplaston treatment0.211591
patients with five0.213355
Arch Pharm Res0.21496
Drugs Exp Clin0.778727
Kumabe T0.215619
Instituto Burzynski0.215357
antineoplaston as2-10.25609
Toxicology studies0.237437
antineoplastones a20.223629
antineoplastón as2-50.218066
inhibitory effect0.218192
Antineoplaston Study Group0.215678
antineoplastón as2-10.256718
clinical study with0.213829
antineoplaston as2-50.211859
Tsuda H0.416032
clinical studies0.21939
Proc Soc Exp0.216295
with five years0.211921
Burzynski B0.287937
Mohabbat MO0.210993
Exp Biol Med0.216836
Integr Cancer Ther0.216474
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.